Publications

Zhou H, Friedman LS, Kabbarah O et al. ORIC-101 Robustly Inhibits the Glucocorticoid Pathway and Overcomes Chemoresistance in TNBC, 2019 San Antonio Breast Cancer Symposium, December 2019.

Metzger T et al. Intratumoral Immunosuppression is Reversed by Blocking Adenosine Production with an Oral Inhibitor of CD73. 2019 AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, October 2019.

Zhou H, Barkund S, Friedman LS et al. ORIC-101 Reverses Glucocorticoid-Driven Resistance to Androgen Receptor Inhibition in CRPC. 2019 AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, October 2019.

Discovery of a Potent Steroidal Glucocorticoid Receptor Antagonist with Enhanced Selectivity against the Progesterone and Androgen Receptors (OP-3633). Du X, Sun D et al. J. Med. Chem. (2019) 62:6751-6764

Discovery of a Potent and Selective Steroidal Glucocorticoid Receptor Antagonist (ORIC-101). Rew Y, Sun D et al. J. Med. Chem. (2018) 61:7767−7784.

Zhou H, Sun J, Fantin VR et al. ORIC-101 reverses a GR-driven EMT-like phenotype and sensitizes TNBC cells to chemotherapy. Poster session presented at: American Academy for Cancer Research Annual Meeting; 2019 March 29-April 4; Atlanta, GA, USA.

Jahchan N, Zhou H, Jackson E, Fantin VR et al. A novel glucocorticoid receptor (GR) antagonist overcomes GR-mediated chemoresistance in triple negative breast cancer. Poster session presented at: American Academy for Cancer Research Annual Meeting; 2018 April 14-18; Chicago, IL, USA.

Jahchan N, Fantin VF et al. Development of murine models to evaluate the impact of glucocorticoid receptor (GR) inhibition on chemotherapy response. Poster session presented at AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2017 October 26-30; Philadelphia, PA, USA.

Zhang H, Jahchan N et al. Activation of AR signaling by Mifepristone enhances prostate cancer growth and impairs enzalutamide response. Poster session presented at: American Academy for Cancer Research Annual Meeting; 2017 April 1-5; Washington, D.C., USA.

Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade. Arora V, et al. Cell (2013) 155: 1309–1322.